Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety

Inclusion Criteria: * A history suggestive of immediate allergy to the food. A convincing clinical history of an IgE mediated reaction to a specific food will be defined as a minimum of 2 mild signs/symptoms or 1 moderate or 1 severe sign/symptom that was likely IgE mediated and occurred within 120 minutes after ingestion or contact * The presence of at least one of the following confirmatory tests: * Positive SPT to the culprit food allergen (weal diameter 3 mm larger than that of the normal saline control). The allergens used will be commercial extracts of the foods (Omega Labs, Toronto, Ontario). * Detection of serum specific IgE (\>0.35 kU/L) to the culprit food or any of its proteins, measured by fluorescence enzyme immunoassay (Phadia, CAP System, Uppsala, Sweden). Exclusion Criteria: * Patients who have uncontrolled respiratory disease (asthma, cystic fibrosis, etc.) * Patients who present with intercurrent disease active at the time of starting desensitization. * Non IgE mediated or non-immunological adverse reactions to milk or peanuts. * Malignant or immunopathological diseases and/or severe primary or secondary immune deficiencies. * Patients receiving oral immunosuppressor therapy. * Patients receiving β-blockers (including topical formulations), or who receive daily doses of NSAIDs, aspirin or ACE inhibitors for cardiac issues. * Associated diseases contraindicating the use of epinephrine: cardiovascular disease, severe hypertension or hypotension. * Patients diagnosed with eosinophilic gastrointestinal disorders, including patients with a history of antacid use for reflux related to food impaction or with a history of esophageal spasm. * Patients already tolerating processed/cooked forms of the food (e.g.,baked goods with milk).